“When we have a patient whose AML has come back, the goal is to get them into a remission so we can take them to a stem cell transplant.,” says Dr. Tara Lin, director, Acute Leukemia Program, University of Kansas Medical Center. This starts with “Drugs such as Ivosidenib or Enasidenib, which are important because they can help us get patients into remission and then bridge to transplant.”
Early trials and published trials of these drugs show that about 30% of these patients will go into remission. Among them, a smaller proportion of patients will go on to have a stem-cell transplant. That smaller proportion reflects that some patients, often older ones, who may choose not to go on to a stem cell transplant for reasons not fully disclosed.
“But that would be the be long-term goal certainly for a younger fit patient with an IDH-1 or IDH-2 mutation whose going to receive these drugs as therapy in relapse,” says Dr. Lin. “The goal would be to put them back into a remission – not with the expectation that these oral drugs will keep them in remission forever – but that we can put them into a deep enough remission so that we can take them on to transplant which, at least, has a potentially curative option.”
Learn more about SurvivorNet's rigorous medical review process.
Dr. Tara Lin is an Associate Professor of Medicine at The University of Kansas Medical Center. She specializes in acute leukemia and cancer stem cell targeted therapies. Read More
“When we have a patient whose AML has come back, the goal is to get them into a remission so we can take them to a stem cell transplant.,” says Dr. Tara Lin, director, Acute Leukemia Program, University of Kansas Medical Center. This starts with “Drugs such as Ivosidenib or Enasidenib, which are important because they can help us get patients into remission and then bridge to transplant.”
Early trials and published trials of these drugs show that about 30% of these patients will go into remission. Among them, a smaller proportion of patients will go on to have a stem-cell transplant. That smaller proportion reflects that some patients, often older ones, who may choose not to go on to a stem cell transplant for reasons not fully disclosed.
Read More “But that would be the be long-term goal certainly for a younger fit patient with an IDH-1 or IDH-2 mutation whose going to receive these drugs as therapy in relapse,” says Dr. Lin. “The goal would be to put them back into a remission – not with the expectation that these oral drugs will keep them in remission forever – but that we can put them into a deep enough remission so that we can take them on to transplant which, at least, has a potentially curative option.”
Learn more about SurvivorNet's rigorous medical review process.
Dr. Tara Lin is an Associate Professor of Medicine at The University of Kansas Medical Center. She specializes in acute leukemia and cancer stem cell targeted therapies. Read More
